H3P17

Across TCGA pan-cancer cohorts, H3P17 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated H3P17 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher H3P17 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated H3P17 expression acts as an unfavorable survival marker, although some lineages such as SKCM and ESCA show a favorable association.

LIHC, GBM, and UCEC are the cancer types where H3P17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.117	0.707	<.001	72	view →
GBM	OS	Tertile	All	0.048	0.416	<.001	54	view →
UCEC	OS	Tertile	All	0.796	0.931	<.001	48	view →
CESC	OS	Tertile	All	0.095	0.585	.038	18	view →
SKCM	DFS	Tertile	All	1.000	0.200	.015	15	view →
ESCA	DFS	Tertile	III,IV	1.000	0.281	.043	12	view →
PAAD	DFS	Tertile	II,III,IV	0.175	0.451	.036	9	view →
KIRP	OS	Tertile	II,III,IV	0.199	0.771	.030	9	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

H3P17–LIHC (OS)

Open the LIHC breakdown →